AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 32, 2015, Pages E4418-E4427

  Pépin, David ^a   Sosulski, Amanda ^a   Zhang, Lihua ^a   Wang, Dan ^b   Vathipadiekal, Vinod ^a   Hendren, Katherine ^a   Coletti, Caroline M ^a   Yu, Aaron ^a   Castro, Cesar M ^a   Birrer, Michael J ^a   Gao, Guangping ^b   Donahoe, Patricia K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

AAV9; Anti Mullerian hormone; MIS; Ovarian cancer; PDX

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; KRUPPEL LIKE FACTOR 4; MUELLERIAN INHIBITING FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; PARVOVIRUS VECTOR; RECOMBINANT PROTEIN; SMAD PROTEIN; TRANSCRIPTION FACTOR SOX2; ANTI-MULLERIAN HORMONE RECEPTOR; HYBRID PROTEIN; RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR MARKER;

ADENO ASSOCIATED VIRUS 9; ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL MEMBRANE; CONTROLLED STUDY; ENHANCER REGION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOSA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALIGNANT ASCITES; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SECRETION RATE; SEMINIFEROUS TUBULE; STABLE EXPRESSION; TISSUE MICROARRAY; TROPISM; TUMOR ENGRAFTMENT; TUMOR GROWTH; TUMOR SPHEROID; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ADULT; AGED; ANIMAL; ASCITES; CARCINOGENESIS; CELL PROLIFERATION; DEPENDOPARVOVIRUS; DRUG SCREENING; GENE THERAPY; GENETICS; METABOLISM; MIDDLE AGED; MULTICELLULAR SPHEROID; MUSCLE; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR CELL LINE; VERY ELDERLY;

ADENO-ASSOCIATED VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-MULLERIAN HORMONE; ASCITES; BIOMARKERS, TUMOR; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; HUMANS; MICE; MIDDLE AGED; MUSCLES; OVARIAN NEOPLASMS; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TISSUE ARRAY ANALYSIS; TRANSGENES; TROPISM; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938904747     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510604112     Document Type: Article

References (78)

1. Burger RA, et al.; Gynecologic Oncology Group (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473-2483.
2. Perren TJ, et al.; ICON7 Investigators (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484-2496.
3. Ledermann J, et al. (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15):1382-1392.
4. Scully RE (1977) Ovarian tumors. A review. Am J Pathol 87(3):686-720.
5. Lee MM, et al. (1997) Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 336(21):1480-1486.
6. Cate RL, et al. (1986) Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 45(5):685-698.
7. Lorenzo HK, et al. (2002) New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci 766(1):89-98.
8. Ragin RC, Donahoe PK, Kenneally MK, Ahmad MF, MacLaughlin DT (1992) Human müllerian inhibiting substance: Enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expr Purif 3(3):236-245.
9. Connolly DC, et al. (2003) Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63(6):1389-1397.
10. Pieretti-Vanmarcke R, et al. (2006) Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res 12(5):1593-1598.
11. Wei X, et al. (2010) Mullerian inhibiting substance preferentially inhibits stem/ progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci USA 107(44):18874-18879.
12. Stephen AE, et al. (2001) Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo. Proc Natl Acad Sci USA 98(6):3214-3219.
13. Stephen AE, et al. (2002) Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8(8):2640-2646.
14. Szotek PP, et al. (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 103(30):11154-11159.
15. Meirelles K, et al. (2012) Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA 109(7):2358-2363.
16. Pépin D, et al. (2013) An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance. Technology (Singap) 1(1):63-71.
17. Gao G, Mueller C, Flotte TR (2010) AAV as a gene therapy vector. Regenerative Therapy for the Musculoskeletal System Using Recombinant Adeno-Associated Viral Vectors, ed Madry MCH (Research Signpost, Kerala, India), pp 1-21.
18. Scott CL, Becker MA, Haluska P, Samimi G (2013) Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 3:295.
19. Dobbin ZC, et al. (2014) Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget 5(18): 8750-8764.
20. Gao GP, et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99(18):11854-11859.
21. Gupta PB, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4):645-659.
22. Elkas JC, et al. (2002) A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 87(2):200-206.
23. Repasky EA, Tims E, Pritchard M, Burd R (1999) Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice. Infect Dis Obstet Gynecol 7(1-2):91-97.
24. Topp MD, et al.; Australian Ovarian Cancer Study (2014) Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 8(3):656-668.
25. Weroha SJ, et al. (2014) Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res 20(5):1288-1297.
26. Xu Y, et al. (1999) Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol 72(2):161-170.
27. Hylander BL, et al. (2013) Origin of the vasculature supporting growth of primary patient tumor xenografts. J Transl Med 11:110.
28. Sivanathan L, Chow A, Wong A, Hoang VC, Emmenegger U (2014) In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes. Prostate 74(5):537-546.
29. Arend RC, et al. (2014) Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer. Gynecol Oncol 134(1):112-120.
30. Bradley A, et al. (2014) EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis 35(5):1100-1109.
31. Crystal AS, et al. (2014) Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346(6216):1480-1486.
32. Fauci JM, et al. (2014) Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol 132(1):203-210.
33. Létourneau IJ, et al. (2012) Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer 12:379.
34. Lee JW, Na DS, Kang JY, Lee SH, Ju BK (2006) Differentiation of mouse p19 embryonic carcinoma stem cells injected into an empty zebrafish egg chorion in a microfluidic device. Biosci Biotechnol Biochem 70(6):1325-1330.
35. Liao J, et al. (2014) Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia- resistant metabolism. PLoS One 9(1):e84941.
36. Shultz LD, et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSzscid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174(10):6477-6489.
37. Chaanine AH, et al. (2014) Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure. Gene Ther 21(4):379-386.
38. Gubrij IB, Martin SR, Pangle AK, Kurten R, Johnson LG (2014) Attenuation of monocrotaline- induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Hum Gene Ther 25(6):498-505.
39. Duque S, et al. (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17(7):1187-1196.
40. Foust KD, et al. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27(1):59-65.
41. McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 5(3):333-338.
42. Mi J, et al. (1999) Recombinant adeno-associated virus (AAV) drives constitutive production of glutamate decarboxylase in neural cell lines. J Neurosci Res 57(1): 137-148.
43. Zhang H, et al. (2011) Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19(8):1440-1448.
44. Kermer P, et al. (2015) BAG1 is neuroprotective in in vivo and in vitro models of Parkinson's disease. J Mol Neurosci 55(3):587-595.
45. Crook ZR, Housman DE (2013) In vivo identification of therapeutic constructs from pooled candidates in HD model mice. J Huntingtons Dis 2(4):437-441.
46. Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL (2014) Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol Ther 22(4):797-810.
47. Franich NR, et al. (2008) AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 16(5):947-956.
48. McBride JL, et al. (2003) Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol 181(2):213-223.
49. Ramaswamy S, Kordower JH (2012) Gene therapy for Huntington's disease. Neurobiol Dis 48(2):243-254.
50. Ramaswamy S, et al. (2009) Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis 34(1):40-50.
51. Southwell AL, Ko J, Patterson PH (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 29(43):13589-13602.
52. Walia JS, et al. (2015) Long-term correction of sandhoff disease following intravenous delivery of rAAV9 to mouse neonates. Mol Ther 23(3):414-422.
53. Rivera VM, et al. (2005) Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105(4): 1424-1430.
54. Xie Y, et al. (2014) AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecol Oncol 135(2):325-332.
55. Bui Nguyen TM, Subramanian IV, Xiao X, Nguyen P, Ramakrishnan S (2010) Adenoassociated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer. Gene Ther 17(5):606-615.
56. Subramanian IV, Ghebre R, Ramakrishnan S (2005) Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther 12(1):30-38.
57. Ferreira V, Petry H, Salmon F (2014) Immune esponses to AAV-vectors, the glybera example from bench to bedside. Front Immunol 5:82.
58. Ferreira V, et al. (2014) Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 25(3):180-188.
59. Salmon F, Grosios K, Petry H (2014) Safety profile of recombinant adeno-associated viral vectors: Focus on alipogene tiparvovec (Glybera-). Expert Rev Clin Pharmacol 7(1):53-65.
60. Lee MM, et al. (1996) Mullerian inhibiting substance in humans: Normal levels from infancy to adulthood. J Clin Endocrinol Metab 81(2):571-576.
61. Clarke TR, et al. (2001) Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Mol Endocrinol 15(6):946-959.
62. Zhan Y, et al. (2006) Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression. Development 133(12):2359-2369.
63. Ha TU, et al. (2000) Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem 275(47):37101-37109.
64. Bakkum-Gamez JN, et al. (2008) Müllerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol 108(1):141-148.
65. Masiakos PT, et al. (1999) Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 5(11):3488-3499.
66. Bergh A, Nikula H, Damber JE, Clayton R, Huhtaniemi I (1985) Altered concentrations of gonadotrophin, prolactin and GnRH receptors, and endogenous steroids in the abdominal testes of adult unilaterally cryptorchid rats. J Reprod Fertil 74(1):279-286.
67. Huhtaniemi I (1995) Molecular aspects of the ontogeny of the pituitary-gonadal axis. Reprod Fertil Dev 7(5):1025-1035.
68. Wang PY, et al. (2005) Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci USA 102(45):16421-16425.
69. Wang PY, et al. (2009) Müllerian inhibiting substance contributes to sex-linked biases in the brain and behavior. Proc Natl Acad Sci USA 106(17):7203-7208.
70. Wittmann W, McLennan IS (2011) The male bias in the number of Purkinje cells and the size of the murine cerebellum may require Müllerian inhibiting substance/anti- Müllerian hormone. J Neuroendocrinol 23(9):831-838.
71. Clarkson AN, et al. (2011) Müllerian inhibiting substance is anterogradely transported and does not attenuate avulsion-induced death of hypoglossal motor neurons. Exp Neurol 231(2):304-308.
72. Hirschhorn T, et al. (2015) Constitutive negative regulation in the processing of the anti-Müllerian hormone receptor II. J Cell Sci 128(7):1352-1364.
73. Greene MR, MacCallum P (2012) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab Press, Plainview, NY), 4th Ed.
74. Hudson PL, et al. (1990) An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 70(1):16-22.
75. Wei W, et al. (2013) FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 123(10):4435-4448.
76. Thériault BL, Portelance L, Mes-Masson AM, Nachtigal MW (2013) Establishment of primary cultures from ovarian tumor tissue and ascites fluid. Methods Mol Biol 1049: 323-336.
77. Latifi A, et al. (2012) Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: Molecular phenotype of chemoresistant ovarian tumors. PLoS One 7(10):e46858.
78. Donahoe PK, Ito Y, Hendren WH, 3rd (1977) A graded organ culture assay for the detection of Mullerian inhibiting substance. J Surg Res 23(2):141-148.